These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2133247)

  • 1. Plasminogen activators and cancer.
    Duffy MJ
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):681-7. PubMed ID: 2133247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer.
    Schmitt M; Jänicke F; Graeff H
    Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urokinase-plasminogen activator in breast cancer: assay by both catalytic and immunoassay.
    Reilly D; Andreasen PA; Duffy MJ
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):47-50. PubMed ID: 1772998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers.
    Duffy MJ
    Biochem Soc Trans; 2002 Apr; 30(2):207-10. PubMed ID: 12023852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase-dependent cell surface proteolysis and cancer.
    Blasi F; Verde P
    Semin Cancer Biol; 1990 Apr; 1(2):117-26. PubMed ID: 2151734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of membrane-bound tissue type and urokinase type plasminogen activators in human breast cancers to estrogen and epidermal growth factor receptors.
    Needham GK; Nicholson S; Angus B; Farndon JR; Harris AL
    Cancer Res; 1988 Nov; 48(22):6603-7. PubMed ID: 3141047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
    Halámková J; Kiss I; Tomášek J; Pavlovský Z; Tuček S; Penka M
    Vnitr Lek; 2012 Feb; 58(2):129-34. PubMed ID: 22463093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors involved in the plasminogen activation system in human breast tumours.
    Damjanovich L; Turzó C; Adány R
    Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis.
    Choong PF; Nadesapillai AP
    Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S46-58. PubMed ID: 14600592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma.
    Gandolfo GM; Conti L; Vercillo M
    Anticancer Res; 1996; 16(4B):2155-9. PubMed ID: 8694536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of plasminogen activators in cancer dissemination. Clinical perspectives].
    Alonso DF; Bal de Kier Joffé E
    Medicina (B Aires); 1992; 52(3):252-6. PubMed ID: 1342692
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B; Zeilhofer HF; Bock KP; Dettmar P; Schmitt M; Kolk A; Pautke C; Horch HH
    J Craniomaxillofac Surg; 2005 Jun; 33(3):191-6. PubMed ID: 15878520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B; Nakamura M; Mori I; Nakamura Y; Kakudo K
    Oncol Rep; 2005 Jul; 14(1):105-12. PubMed ID: 15944776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
    Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.